Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of QLM3003 in Healthy Adults
NCT05932888Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atopic dermatitis (AD) comparing QLM3003 with Placebo (2 arms). Primary endpoint: Incidence of Local and Systemic Adverse Events at 8 days. Started Jun 2023; status: completed.
02
Drugs
QLM3003
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05932888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932888.